文献速递皮肤肿瘤

重定位黑色素瘤化疗以激活炎症小体治疗BRAF/MAPK抑制剂耐药黑色素瘤

Repurposing Melanoma Chemotherapy to Activate Inflammasomes in the Treatment of BRAF/MAPK Inhibitor Resistant Melanoma.
PubMed 文献 · J Invest Dermatol · 2021-10-22

该研究利用BRAF V600抑制剂耐药前后的患者来源黑色素瘤细胞系,在体外及NOD scid gamma小鼠异种移植模型中测试替莫唑胺联合或不联合氯喹(抑制自噬)的效果。结果显示,具有炎症性未分化状态的耐药黑色素瘤对该联合方案敏感,且涉及的炎症小体与死亡机制在黑色素瘤间存在差异(AIM2或NLRP3,gasdermin D或E)。

要点

  • 耐药黑色素瘤常伴MAPK通路上调及未分化状态。
  • 替莫唑胺联合氯喹在耐药黑色素瘤中显示体外及体内敏感性。
  • 炎症小体与死亡机制因黑色素瘤而异,涉及AIM2或NLRP3。

核心结论

  • 具有炎症性未分化状态的BRAF抑制剂耐药黑色素瘤可能对替莫唑胺联合氯喹敏感。
  • 该联合方案在体外及NOD scid gamma小鼠异种移植模型中观察到敏感性。

研究设计与样本

  • 研究采用患者来源的BRAF V600抑制剂耐药前后黑色素瘤细胞系。
  • 在体外及非肥胖糖尿病scid gamma小鼠异种移植模型中进行测试。
  • 耐药黑色素瘤暴露于替莫唑胺,联合或不联合氯喹抑制自噬。

主要发现

  • 具有炎症性未分化状态的黑色素瘤在体外和体内对联合方案显示敏感。
  • 涉及的炎症小体在黑色素瘤间存在差异,为AIM2或NLRP3。
  • 涉及的死亡机制在黑色素瘤间存在差异,为gasdermin D或E。

临床怎么用

  • 耐药黑色素瘤的炎症状态可能作为选择炎症小体靶向治疗患者的生物标志物。
  • 替莫唑胺联合氯喹可能为BRAF/MAPK抑制剂耐药黑色素瘤提供治疗策略。

局限性

  • 研究为初步体外及小鼠模型研究,结果尚未在患者中转化验证。
  • 不同黑色素瘤对炎症小体的选择性和化疗靶向选择性尚不明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The development of resistance to treatments of melanoma is commonly associated with an upregulation of the MAPK pathway and the development of an undifferentiated state. Previous studies have suggested that melanoma with these resistance characteristics may be susceptible to innate death mechanisms such as pyroptosis triggered by the activation of inflammasomes. In this study, we have taken cell lines from patients before and after the development of resistance to BRAF V600 inhibitors and exposed the resistant melanoma to temozolomide (a commonly used chemotherapy) with and without chloroquine to inhibit autophagy. It was found that melanoma with an inflammatory undifferentiated state appeared susceptible to this combination when tested in vitro and in vivo against xenografts in nonobese diabetic scid gamma mice. Translation of the latter results into patients would promise durable responses in patients treated by the combination. The inflammasome and death mechanism involved appeared to vary between melanoma and involved either AIM2 or NLRP3 inflammasomes and gasdermin D or E. These preliminary studies have raised questions as to the selectivity for different inflammasomes in different melanoma and their selective targeting by chemotherapy. They also question whether the inflammatory state of melanoma may be used as biomarkers to select patients for inflammasome-targeted therapy.

来源:J Invest Dermatol,查看原文。版权归原作者所有。

引用

  1. Ahmed F, Tseng HY, Ahn A, et al. Repurposing Melanoma Chemotherapy to Activate Inflammasomes in the Treatment of BRAF/MAPK Inhibitor Resistant Melanoma. J Invest Dermatol. 2021. PMID: 34695412. doi:10.1016/j.jid.2021.09.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。